The most frequently occurring gain-of-function JAK2 V617F mutation gives rise to a constitutively active JAK2 kinase, which drives the JAK/STAT signaling that leads to excessive proliferation and survival of myeloid progenitor cells and accounts for >95% of driver mutations in PV and >55% in ET and PMF. This evidence concerns the gene JAK2 and acquired polycythemia vera.